126 related articles for article (PubMed ID: 38193270)
41. A Cohort Study on the Safety and Efficacy of Warfarin and Rivaroxaban in Anticoagulant Therapy in Patients with Atrial Fibrillation Study.
Wang L; Yao W
Biomed Res Int; 2022; 2022():4611383. PubMed ID: 35845939
[TBL] [Abstract][Full Text] [Related]
42. Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment-A nationwide register-based study.
Glise Sandblad K; Schulman S; Rosengren A; Sörbo J; Philipson J; Hansson PO
J Intern Med; 2023 Dec; 294(6):743-760. PubMed ID: 37641391
[TBL] [Abstract][Full Text] [Related]
43. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin.
Coleman CI; Costa OS; Brescia CW; Vardar B; Abdelgawwad K; Sood N
Cardiovasc Diabetol; 2021 Feb; 20(1):52. PubMed ID: 33637082
[TBL] [Abstract][Full Text] [Related]
44. Management of anticoagulation with rivaroxaban in trauma and acute care surgery: Complications and reversal strategies as compared to warfarin therapy.
Myers SP; Dadashzadeh ER; Cheung J; Alarcon L; Kutcher M; Brown JB; Neal MD
J Trauma Acute Care Surg; 2017 Mar; 82(3):542-549. PubMed ID: 28045742
[TBL] [Abstract][Full Text] [Related]
45. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m).
Marshall A; Levine M; Hill C; Hale D; Thirlwall J; Wilkie V; French K; Kakkar A; Lokare A; Maraveyas A; Chapman O; Arif A; Petrou S; Maredza M; Hobbs R; Dunn JA; Young AM
J Thromb Haemost; 2020 Apr; 18(4):905-915. PubMed ID: 31995662
[TBL] [Abstract][Full Text] [Related]
46. Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease.
Ahuja T; Sessa K; Merchan C; Papadopoulos J; Green D
Adv Hematol; 2021; 2021():8870015. PubMed ID: 33628255
[TBL] [Abstract][Full Text] [Related]
47. Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies.
Chan YH; Chan CY; Chen SW; Chao TF; Lip GYH
Europace; 2023 Oct; 25(10):. PubMed ID: 37738425
[TBL] [Abstract][Full Text] [Related]
48. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
[TBL] [Abstract][Full Text] [Related]
49. Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.
de Jong LA; Gout-Zwart JJ; van den Bosch M; Koops M; Postma MJ
J Med Econ; 2019 Apr; 22(4):306-318. PubMed ID: 30614320
[TBL] [Abstract][Full Text] [Related]
50. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
[TBL] [Abstract][Full Text] [Related]
51. Clinical outcomes and plasma clot permeability and lysability in patients with venous thromboembolism on rivaroxaban: a cohort study.
Frączek P; Krzysztofik M; Stanisz A; Undas A
Pol Arch Intern Med; 2019 Jun; 129(6):377-385. PubMed ID: 31063157
[TBL] [Abstract][Full Text] [Related]
52. Comparison of the Safety and Efficacy of Direct Oral Anticoagulants and Warfarin in Atrial Fibrillation or Venous Thromboembolism in Patients with Renal Impairment: Systematic Review, Meta-Analysis and Network Meta-Analysis.
Wang Z; Xiang Q; Hu K; Zhang X; Xie Q; Liu Z; Cui Y
Am J Cardiovasc Drugs; 2021 Nov; 21(6):643-657. PubMed ID: 33817758
[TBL] [Abstract][Full Text] [Related]
53. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
[TBL] [Abstract][Full Text] [Related]
54. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
55. Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis.
Costa OS; Thompson S; Ashton V; Palladino M; Bunz TJ; Coleman CI
Thromb J; 2020; 18():6. PubMed ID: 32292291
[TBL] [Abstract][Full Text] [Related]
56. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
[TBL] [Abstract][Full Text] [Related]
57. Rivaroxaban for prevention and treatment of venous thromboembolism.
Chan NC; Weitz JI
Future Cardiol; 2019 Mar; 15(2):63-77. PubMed ID: 30779598
[TBL] [Abstract][Full Text] [Related]
58. Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns.
Ghanima W; Schultze A; Donaldson R; Brodin E; Halvorsen S; Graham S; Carroll R; Ulvestad M; Lambrelli D
Clin Ther; 2021 Jul; 43(7):1179-1190.e3. PubMed ID: 34083030
[TBL] [Abstract][Full Text] [Related]
59. Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017.
Lutsey PL; Walker RF; MacLehose RF; Alonso A; Adam TJ; Zakai NA
Res Pract Thromb Haemost; 2019 Oct; 3(4):668-673. PubMed ID: 31624786
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.
Tellor KB; Patel S; Armbruster AL; Daly MW
J Clin Pharm Ther; 2015 Aug; 40(4):447-51. PubMed ID: 26010016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
